Nvr Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 29 Days
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.14 M
- Revenue Growth 78.23%
- Profit Growth 383.25%
- Ebitda 385.70%
- Net Worth 8.04%
- Total Assets 117.78%
About Nvr Life Sciences
Nvr Life Sciences Private Limited (NLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 January 2012 and has a history of 13 years. Its registered office is in Karnal, Haryana, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.14 M.
Vikas Malik and Rajpal Malik serve as directors at the Company.
Company Details
-
Location
Karnal, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232HR2012PTC044756
-
Company No.
044756
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Jan 2012
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Nvr Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Malik
|
Director | 10-Jan-2012 | Current |
|
Rajpal Malik
|
Director | 10-Jan-2012 | Current |
Financial Performance of Nvr Life Sciences.
Nvr Life Sciences Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 78.23% increase. The company also saw a substantial improvement in profitability, with a 383.25% increase in profit. The company's net worth moved up by a moderate rise of 8.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nvr Life Sciences?
In 2016, Nvr Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.14 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 0.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 May 2021 | Indian Bank | ₹0.19 M | Open |
| 12 Oct 2017 | Indian Bank | ₹0.95 M | Open |
How Many Employees Work at Nvr Life Sciences?
Unlock and access historical data on people associated with Nvr Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nvr Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nvr Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.